COMP Compass
- 4.120
- +0.220+5.64%
- 4.150
- +0.030+0.73%
Compass News
How Major US Stock Indexes Fared Monday, 5/13/2024
US STOCKS-S&P 500 Edges Down, Investors and Consumers Wary of Inflation
Compass Adds Parks Real Estate to Expand in Southeastern US
Compass (COMP) said Monday that it has added Parks Real Estate, a residential real estate firm in Tennessee, to strengthen its presence in the southeast. The company said Parks has over 1,500 agents a
Compass Strengthens Footprint in Southeastern U.S., Welcoming the Top Brokerage in Tennessee
NEW YORK, May 13, 2024 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass"), the largest residential real estate brokerage in the United States by sales volume1, announces the addition of Parks Rea
US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase
GLOBAL MARKETS-Stocks Climb, Dollar Dips as Focus Shifts to US Inflation Data
COMPASS Pathways Plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
US STOCKS-Wall St Inches up With Inflation Prints in Focus
Stock Market News for May 13, 2024
Compass Therapeutics Q1 EPS $(0.08) Beats $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 33.33 percent decrease over losses of
Top 3 Blue-Chip Picks as Dow Posts an Eight-Day Winning Run
Beat the Market the Zacks Way: Micron, Freshpet, Colgate-Palmolive in Focus
Compass Point Adjusts Truist Financial's Price Target to $43 From $42
Truist Financial (TFC) has an average rating of outperform and price targets ranging from $34 to $50, according to analysts polled by Capital IQ. Price: 39.10, Change: -0.37, Percent Change: -0.94
Press Release: Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update -- Received FDA Fast Track Designation for the investigation of CTX-009 in combination with pa
Compass Therapeutics 1Q Loss/Shr 8c >CMPX
Compass Therapeutics 1Q Loss/Shr 8c >CMPX
Compass Therapeutics 1Q Loss $10.8M >CMPX
Compass Therapeutics 1Q Loss $10.8M >CMPX
Futures Edge Higher at Start of Data-heavy Week
HC Wainwright & Co. : The Compass Pathways (CMPS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $120.00.
HC Wainwright & Co. : The Compass Pathways (CMPS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $120.00.
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways with a Buy and maintains $120 price target.
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
Analysis
Price Target
No Data
